Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

Renee Bullock-Palmer, MD, director, non-invasive cardiac imaging, at the Deborah Heart and Lung Center, explains CT calcium scoring can determine if a patient needs to take aspirin and statins for prevention of coronary disease.

Advanced cardiac imager Roosha Parikh, MD, explained that cardiac amyloidosis is regularly misdiagnosed. It can often be identified in echocardiography results, however, if physicians know how to identify it. 

“It's very important,” one cardiologist said. “This is a life-saving test and it's very frustrating that we can't access the medication.”

Browse through some of the many highlights from the American Society of Echocardiography's 2023 annual meeting. 

The American Medical Association Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe.

The results of a study published in Radiology: Cardiothoracic Imaging call into question the value of initiating aspirin therapy in certain instances.

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.